Clinical Trial Update: Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads [Phase 2]

View source ↗

Summary

A Phase 2 trial of nivolumab for patients with Stage IV or recurrent non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer | Phase 2 | Status: WITHDRAWN